작성일 : 25-05-16 15:13
|
오션파라 다이스7 ㎙ 14.ruk737.top ㎙ 릴게임추천사이트
|
|
|
작성자 :
삼수세살
조회 : 148
|
【95.ruk737.top】
릴게임사이트오리지날 양귀비릴게임알라딘황금성배당
무료슬롯 얌얌 ㎙ 55.ruk737.top ㎙ 무료 야마토게임
온라인 손오공 릴게임 ㎙ 87.ruk737.top ㎙ 황금성게임다운
릴게임골드몽 ㎙ 54.ruk737.top ㎙ 온라인슬롯머신
일본빠징고 ㎙ 88.ruk737.top ㎙ 바다이야기 무료게임 다운로드
무료충전 릴 게임 온라인게임순위 2018 피망로우바둑이 바다게임이야기 최신 릴게임 최신야마토 온라인바다이야기 오징어 릴게임 바다이야기주소 손오공릴게임다운로드 슬롯 무료 사이트 릴게임오션 야마토릴게임 온라인룰렛 온라인 릴게임 사이트 야마토동영상 슬롯 추천 디시 슬롯 머신 제작 프라그마틱 슬롯 팁 황금성 무료머니 바다이야기릴게임 실시간릴게임사이트 바다이야기고래 바다이야기파칭코 양귀비 릴게임 손오공 게임 다운 손오공릴게임예시 황금성게임예시 온라인 릴게임 PC 슬롯 머신 게임 강원랜드게임종류 사설배팅 바다이야기 예시 일본 파칭코 무료 충전 바다이야기 릴게임황금포카성 릴게임골드몽사이트 슬롯 바다이야기 황금고래 빠찡코 하는 방법 릴게임오션파라다이스 전함야마토 알라딘게임다운 최신게임 무료 바다이야기 손오공릴게임다운로드 캡틴프라이드게임 바다이야기 황금고래 피망로우바둑이 안전 슬롯사이트 바다이야기사이트먹튀 릴게임신천지 야마토온라인주소 황금성하는곳 바다이야기부활 릴게임오션파라다이스 황금성다운로드 오락실게임 없습니다. 바다이야기 부활 릴박스 바다이야기 게임방법 릴게임손오공게임 파라다이스오션 야마토게임하기� 백경게임사이트 야마토 꽁머니 오션바다이야기게임 바다게임사이트 바다게임이야기 야마토릴게임 릴게임정글북 릴게임알라딘주소 무료바다이야기게임 체리게임주소 무료게임 카카오 야마토 먹튀 바다이야기먹튀돈받기 먹튀피해복구 온라인예시게임 바다이야기 파일 무료충전 릴 게임 카지노 슬롯머신 잭팟 오리지널야마토2게임 바다이야기먹튀 오션파라다이스7게임 바다 이야기 다운 황금성게임장 릴게임이벤트 바다이야기 먹튀 돈 받기 손오공 게임 다운 슬롯 검증사이트 손오공게임 오션파라다이스 온라인 오리 지날황금성 무료슬롯게임 황금성다운로드 바다신게임 무료충전 바다이야기 바다이야기사이트먹튀 바다이야기게임공략방법 파칭코게임다운로드 신규 릴게임 온라인야마토2 다빈치 신천지 무료게임 오락실게임 파라다이스 황금성게임공략 법 슬롯머신 무료 릴게임연타 무료인터넷바다이야기 신천지게임 하는방법 릴게임사이트 황금성 제주도 바다이야기하는법 온라인 릴게임 정보 럭키세븐 바다이야기 먹튀 신고 릴게임용의눈 슬롯 머신 이기는 방법 빠징코 슬롯머신 바다이야기 기프트 전환 스톰게임 pc릴게임 [Shin-Min Joon, Edaily Reporter] Huons Global reported on May 15 its consolidated financial results for this year‘s January March period.
Huons Global CI. (Image=Huons Global)
The company reported 199.1 billion won in consolidated sales, 25.6 billion won in operating profit, and 26.1 billion won in net pro증권투자사이트
fit, reflecting year on year changes of -1.4%, -1.5%, and +13.1%, respectively.
Huons Global said that consolidated revenue for the first quarter fell compared to the same period 황금성게임설명
last year, but with improved performances in the group’s core businesses: growth in ethical drug (ETC) business for Huons and strong aesthetic exports for Humedix.
The group improved managem텐스탁
ent efficiency and reduced selling, general, and administrative (SG&A) expenses, while increased R&D investments for future growth, resulting the operating profit for the first quarter to fall year ov릴게임 사이트
er year.
The Huons Group said that R&D investment for the first quarter rose 34% to 17.8 billion won from 13.3 billion won in the same period last year. The group attributed the increase in 주식성공담
R&D spending to efforts to secure key new drug candidates (pipelines) and its clinical trial costs for Huons and Huonslab.
Huons (CEO Song Soo young) reported consolidated sales of 145.8 billion won, operating profit of 12.8 billion won, and net profit of 12.3 billion won, reflecting year-on-year changes of -1.3%, +20.1%, and +26%, respectively.
Huons’ ETC business showed improved performance driven by continued growth in chronic disease drugs and increased exports of injections to the U.S. and eye drops to the rest of the world.
On May 2 Huons received two U.S. Food and Drug Administration’s (FDA) Abbreviated New Drug Application (ANDA) approvals, the two additions to its five FDA approvals for injections. This accelerates Huons’ exports expansion efforts to North America. The company continued stable performance in CMO business, powered by increased operation rate of the eye drop line at the second production facility.
Huons significantly improved its profitability as a result of improved performance of its subsidiaries and cost management efforts. Huons reported consolidated operating profit margin of 8.8%, separate operating profit margin of 9.8%. This marks the highest quarterly operating profit margin since 2024.
Huons N, a spin off of Huons’ health functional food business newly-launched on May 2, turned in profit in the first quarter with sales of 11.7 billion won and operating profit of 200 million won. HuonsLifeSciences drastically reduced the deficit, reporting its first quarter sales of 5.8 billion won and operating loss of 50 million won.
Humedix (CEO Kang Min jong), an aesthetic subsidiary of Huons Group, reported its first quarter separate sales of 40.1 billion won, operating profit of 11.4 billion won, and net profit of 13.4 billion won, reflecting year on year changes of -2.5%, +7.3%, and +45%, respectively.
Humedix’s performance growth was driven by filler exports, cosmetics, and active pharmaceutical ingredients (API) businesses. In particular, hyaluronic acid (HA) filler showed strong performance.
Since last year, its exports to Brazil continued to grow, and early this year, the company obtained approvals from Thailand on three filler products.Humedix plans to focus on filler exports, leading to steady sales growth. Humedix’s operating profit increased in the first quarter due to improved operating rate of the facility and profitability driven by increased filler exports and API sales.
HuM&C (CEO Kim Jun cheol) a subsidiary specialized in healthcare components, reported its first quarter consolidated sales of 12.5 billion won, operating profit of 512 million won, and net profit of 302 million, with year-on-year changes of +4.4%, -49.6%, and -76.4%, respectively.
HuM&C’s glass business recorded sales of 7.4 billion won, a slight decrease from the previous year, on the other hand, the cosmetics business showed significant growth, recording 5.1 billion won. HuM&C attributed this 77.2% increase to the effects of the business acquisition in the second half of last year.
In the second quarter, HuM&C expects ramp up of its production facility’s operation in Vietnam to strengthen its competitiveness in the glass business.
Huons BioPharma, a subsidiary specializing in botulinum toxin, reported its first quarter sales of 7.2 billion won and operating profit of 1.4 billion won. Overseas sales of toxin products to Thailand and Iraq has increased, but decrease in domestic sales resulted in both sales and operating profit to fall compared to the same period last year.
Huons Meditech recorded sales of 13.3 billion won and an operating loss of 230 million won due to the decrease in exports of medical devices, resulting in a decrease in sales and turning it into a deficit. Food Assemble, a subsidiary specialized in meal kits, recorded 2.4 billion won in sales and reduced its deficit with 517 million won in operating loss.
Huonslab is actively continuing R&D on human hyaluronidase ‘HLB3-002’. It is currently undergoing a pivotal Phase 1 clinical trial in South Korea. Following the completion of the trial, Huonslab plans to apply for approval to MFDS in the second half of this year. Last month, Huonslab announced the result of formulation conversion using ‘HLB3-002’ in a poster presentation at the 2025 Annual Meeting of the American Association for Cancer Research (AACR 2025).
CEO of Huons Global, Song Soo young said “Huons Group will deliver tangible results and secure mid- to long-term growth engines by vowing to step up overseas expansion and R&D investment. We will continue to strengthen compliance and legal management and become a global healthcare leading company that continues to thrive on corporate ethics.”
Huons Global has co CEOs Yoon Sung tae and Song Soo young. Chairman Yoon Sung tae was appointed as Huons Global’s CEO by the board after the 38th annual general meeting of shareholders. Chairman Yoon has been returned to the front lines of management to lead the group’s great leap forward, marking its 60th anniversary this year. His main focus is on expanding its global reach, and securing competitive pipelines through R&D.
신민준 (adonis@edaily.co.kr)
|
|
